G2 Industry Buzz: Pharmacogenomics Paving the Way at Maryland Hospitals
Cardiac stenting and catheterization patients at the University of Maryland Medical Center (UMMC) and Baltimore VA Medical Center are now undergoing genetic tests to better shape their post-treatment options and decisions.The patients are being tested for variations in the CYP2C19 gene, which can lead to different rates of metabolization of clopidogrel, a widely used anti-clotting drug marketed as Plavix. It is suspected that as many as a quarter of the U.S. population has a gene variant that makes them react differently to standard dosages of Plavix. “Knowing a patient’s genotype is helping us to make more informed decisions for our patients,” said Mark R.Vesely, M.D., a cardiologist who practices at both hospitals and also teaches at the University of Maryland’s School of Medicine. “A combination of aspirin and clopidogrel is the routine choice of medications many physicians will prescribe for their stent patients. But patients who are likely to have a poor or moderate response may be better protected by other medications or possibly a higher dose of clopidogrel. It comes down to what is best for each patient.” The CYP2C19 test ranges in price from about $200 to $500. It is being offered free to the UMMC and VA […]
Subscribe to view Essential
Start a Free Trial for immediate access to this article